Roche Media News

Roche to present extensive data showcasing its industry-leading ophthalmology portfolio at ARVO 2026

5 days ago

New real-world data confirm Vabysmo’s potent retinal drying in nAMD and DMEKey...

[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong sales growth of +6% at constant exchange rates in the first quarter of 2026; -5% in CHF due to the significant appreciation of the Swiss franc

12 days ago

Group sales were +6% at constant exchange rates (CER)1, -5% when reported...

Roche’s fenebrutinib significantly reduced relapses versus standard of care to approximately one every 17 years in RMS

13 days ago

Late-breaking Phase III FENhance 1 and 2 study results showed superiority of...

Roche’s ENSPRYNG (satralizumab) reduces risk of relapses by 68% demonstrating potential to become first treatment for MOGAD

13 days ago

Phase III METEOROID study met its primary endpoint in patients with myelin...

FDA accepts application for Roche’s Gazyva/Gazyvaro for the treatment of the most common form of lupus

14 days ago

Filing acceptance based on phase III ALLEGORY data for Gazyva/Gazyvaro showing a...

Roche receives CE mark for new Elecsys NfL blood test to detect neuroinflammation in multiple sclerosis

22 days ago

The Elecsys NfL blood test detects neuroaxonal damage associated with neuroinflammation in...

Roche launches the cobas MPX-E assay, a new 4-in-1 donor screening test to further safeguard the global blood supply

about 1 month ago

The cobas MPX-E test provides four critical results (for HIV, HCV, HBV...

https://www.roche.com/media/releases/med-cor-2026-03-23

about 1 month ago

Roche launches NVIDIA AI factory to accelerate the development of new therapeutics and diagnostics solutions

about 2 months ago

With the addition of 2,176 NVIDIA Blackwell GPUs, Roche now operates the...

Roche Annual General Meeting 2026

about 2 months ago

Shareholders approved all proposals of the Board of Directors Severin Schwan re-elected...

[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on phase III persevERA study in ER-positive advanced breast cancer

about 2 months ago

persevERA Breast Cancer study did not meet the primary objective of a...

New England Journal of Medicine publishes phase III ALLEGORY data showing Roche’s Gazyva/Gazyvaro significantly reduces disease activity in the most common form of lupus

about 2 months ago

Over three quarters of people on Gazyva/Gazyvaro plus standard therapy achieved at...